Abstract:Objectives To assess the effectiveness and safety of carnitine in the treatment of idiopathic asthenozoospermia.Methods The Cochrane Library,MEDLINE,EMbase,and CNKI were searched between Jan 1995 and Dec 2006.Both English and Chinese studies were included in the review if they were randomized controlled trials(RCTs)involving men with idopathic asthenozoospermia who were treated with carnitine.Trial screening,data extraction,and quality assessment of included trials were conducted by method recommended by Cochrane Collaboration.Statistical analysis was conducted using RevMan 4.2.10 software.Results Five RCTs involving 346 patients met the inclusion criteria,and 307 patients were included in the meta-analysis.The results showed that:after being treated with carnitine for 3 and 6 months,the difference of the patients' partners' spontaneous pregnancy rate between treatment group and control group was statistically significant with RR2.46 and 95% CI1.12 to 5.43(Z=2.23,P=0.03).After being treated with carnitine for 3 and 6 months,the difference of forward motile sperm per ejaculate between treatment group and control group was not statistically significant with WMD 9.16 and 95%CI 0.14 to 18.18(Z=1.99,P=0.05)and WMD 5.28 and 95%CI –4.45 to 15.01(Z=1.06,P=0.29).After being treated with carnitine for 3 and 6 months,the difference of percentage of forward sperm motility between treatment group and control group was not statistically significant with WMD 14.56 and 95%CI –4.49 to 33.61(Z=1.50,P=0.13),and WMD 7.34 and 95%CI –5.93 to 20.61(Z=1.08,P=0.28).After being treated with carnitine for 3 and 6 months,the difference of total motile sperm per ejaculate between treatment group and control group was not statistically significant with WMD 15.32 and 95%CI –1.34 to 31.98(Z=1.80,P=0.07)and WMD 6.20,95%CI –3.00 to 15.39(Z=1.32,P=0.19).After being treated with carnitine for 3 and 6 months,the difference of percentage of total sperm motility between treatment group and control group was not statistically significant with WMD 2.97 and 95%CI –5.75 to 11.69(Z=0.67,P=0.50)and WMD 4.48 and 95%CI-9.17 to18.14(Z=0.64,P=0.52).After being treated with carnitine for 3 and 6 months,the difference of semen volume between treatment group and control group was not statistically significant with WMD –0.12 and 95%CI –0.55 to 0.30(Z=0.57,P=0.57)and WMD 0.03 and 95%CI –0.38 to 0.45(Z=0.16,P=0.87).After being treated with carnitine for 3 and 6 months,the difference of sperm concentration between treatment group and control group was not statistically significant with WMD 7.92 and 95%CI – 2.85 to18.68(Z=1.44,P=0.15),and WMD 1.02 and 95%CI –5.09 to 7.14(Z=0.33,P=0.74).Three RCTs reported that there were no serious side effects of carnitine during the treatment period.Conclusions The available evidence indicates that spontaneous pregnancy rate would increase with carnitine therapy,while it is short of improvement of semen parameters.There is no serious side effect of carnitine.Because of lack of evidence,we cannot conclude that carnitine is effective in improving the prognosis of infertile patients with idiopathic asthenozoospermia.More high quality trials with large sample are proposed.

[Expressions of Sperm-Specific Genes in Carnitine-Cultured Testis Sperm of Obstructive Azoospermia Patients].

Carnitine in the Treatment of Idiopathic Asthenozoospermia: A Systematic Review

Double‐blind, randomised, placebo‐controlled trial on the effect of L‐carnitine and L‐acetylcarnitine on sperm parameters in men with idiopathic oligoasthenozoospermia

Supplementation with L-Carnitine Rescues Sperm Epigenetic Changes in Asthenospermic Male Semen with Altered Acetyl-L-Carnitine Levels

[A Controlled Randomized Trial of the Use of Combined L-carnitine and Acetyl-L-carnitine Treatment in Men with Oligoasthenozoospermia].

Study on establishment of rat model with asthenospermic and melioration of asthenospermic treated by L-carnitine

[L-Carnitine Improves the Reproductive Function of Male Rats with Ornidazole-Induced Asthenospermia].

Effect of L-carnitine And/or L-acetyl-carnitine in Nutrition Treatment for Male Infertility: a Systematic Review.

Protective effect of L‐carnitine on apoptosis, DNA fragmentation, membrane integrity and Lipid peroxidation of spermatozoa in the asthenoteratospermic men

Correlation between seminal plasma biochemical markers and semen parameters in idiopathic oligoasthenoteratospermia: identification of biomarkers for L-carnitine therapy

OCTN2 expression and function in the Sertoli cells of testes from patients with non-obstructive azoospermia

The effects of L-carnitine and fructose in improved Ham's F10 on sperm culture in idiopathic severe asthenospermia within 24h

The Influence of L-Carnitine on the Expression of Mirnas in Asthenospermia Spermatozoa and the Network Regulation of the Associated Molecules.

Chronic oral administration of L-carnitine induces testicular injury: in vivo evidence

Acetyl-L-carnitine: an Effective Antioxidant Against Cryo-Damage on Human Spermatozoa with Asthenospermia

The efficacy of orally administered L-carnitine in alleviating ovarian dysfunctions has laid the foundation for targeted in vivo use: a study employing self-control and propensity score matching

The antioxidant roles of L-carnitine and N-acetyl cysteine against oxidative stress on human sperm functional parameters during vitrification

Carnitine traffic and human fertility

Seminal Plasma Levocarnitine Significantly Correlated with Semen Quality

Correlation analysis of seminal plasma free testosterone and L-carnitine with semen parameters

[L-carnitine-astaxanthin compound nutrients for the treatment of idiopathic oligospermia and asthenozoospermia: A multicenter clinical observation]